About CellBion
CellBion is a company based in Seoul (South Korea) founded in 2010.. CellBion operates in a competitive market with competitors including ARTMS, NorthStar Medical Radioisotopes, Niowave, Nanovista and Ground Fluor Pharmaceuticals, among others.
- Headquarter Seoul, South Korea
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Cellbion Co., Ltd
-
Annual Revenue
$1.55 M (USD)55.64as on Dec 31, 2024
-
Net Profit
$-4.93 M (USD)-100.01as on Dec 31, 2024
-
EBITDA
$-4.41 M (USD)-47.14as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CellBion
CellBion is a publicly listed company on the KRX with ticker symbol 308430 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of CellBion
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by CellBion
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CellBion
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellbion Comparisons
Competitors of CellBion
CellBion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ARTMS, NorthStar Medical Radioisotopes, Niowave, Nanovista and Ground Fluor Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Radioisotope technologies and services are developed and provided by ARTMS.
|
|
| domain | founded_year | HQ Location |
Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market
|
|
| domain | founded_year | HQ Location |
Devices and radioisotopes for nuclear imaging are provided by Niowave.
|
|
| domain | founded_year | HQ Location |
Multimodal visualization agents are developed for image-guided interventions.
|
|
| domain | founded_year | HQ Location |
Proprietary chemistry for pharmaceutical synthesis is developed by the company.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellbion
Frequently Asked Questions about CellBion
When was CellBion founded?
CellBion was founded in 2010.
Where is CellBion located?
CellBion is headquartered in Seoul, South Korea.
Who is the current CEO of CellBion?
Kweon Kim is the current CEO of CellBion.
What is the annual revenue of CellBion?
Annual revenue of CellBion is $1.55M as on Dec 31, 2024.
What does CellBion do?
CellBion was founded in 2010 in Seoul, South Korea, within the biotechnology sector. Radioisotope probes for imaging are produced, focusing on diagnostic agents for PET-CT, PET-MRI, and blood vessel imaging in atherosclerosis patients. Therapeutic applications are also developed, including treatments for cardio and cerebrovascular conditions. The technology is applied additionally in the food industry for various uses.
Who are the top competitors of CellBion?
CellBion's top competitors include ARTMS, NorthStar Medical Radioisotopes and Niowave.
Is CellBion publicly traded?
Yes, CellBion is publicly traded on KRX under the ticker symbol 308430.
What is CellBion's ticker symbol?
The ticker symbol of CellBion is 308430 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.